Turn early oncology complexity into clearer decisions
Early phase oncology trials evaluate new cancer therapies in patients while establishing safety, determining appropriate dose levels and assessing early evidence of biological or clinical activity. They may include first-in-human, Phase I, Phase Ib and early Phase II studies, with dose-escalation, optimisation and expansion cohorts shaped by emerging safety, pharmacokinetic, pharmacodynamic, biomarker and response data.
Clarenta brings clinical development strategy and study delivery together around those decisions. We help biotech and pharmaceutical teams plan and run early phase oncology trials across Europe, keeping scientific intent, patient access, operations and data review connected as the programme evolves.
Why early phase oncology trials need specialist support
In oncology, early development usually begins in patients with advanced cancers rather than healthy volunteers. Eligibility can depend on tumour type, molecular profile, prior treatment and disease status. Cohorts may open, pause or change as safety and activity data emerge. Each decision affects the protocol, sites, patients, supply, data and timelines.
The right early phase oncology CRO sees these dependencies before they become delays. Clarenta works alongside your team to define what the study needs to answer, anticipate where the design may need to adapt and keep the functions behind each decision moving together.
Early phase oncology CRO services built around your study
Clinical development and study strategy
Protocol, regulatory and start-up planning
Feasibility, sites and patient access
Clinical operations and project leadership
Medical, safety and data oversight
Biomarker, laboratory and sample strategy
Early phase oncology experience across indications and modalities
Clarenta’s early phase oncology experience covers more than 70 studies across solid tumours and haematologic malignancies. This includes first-in-human, dose-escalation, PK, precision oncology, basket and combination-treatment studies. Our teams bring clinical development strategy and operational experience together across the indications, populations and study designs that shape early oncology programmes.
Our teams bring experience across monoclonal antibodies, bispecific antibodies, cell therapies, other biologics, small molecules and biosimilars. We work with biotech and emerging pharmaceutical companies that need close scientific guidance, visible operational leadership and the flexibility to respond as evidence develops.
Why partner with Clarenta for your early phase oncology trials?
Early guidance connected to delivery
The people shaping the strategy stay close to execution, so the scientific intent is not lost as the study moves from protocol to sites and patients.
Pan-European reach with local context
We combine European coverage with country-level regulatory, site and patient insight, helping sponsors choose a delivery model that fits the indication and development objective.
Visibility when decisions matter
Your programme remains visible. Senior team members stay accessible, risks are raised early and recommendations come with the context needed to act.
The right scale for biotech companies
Clarenta brings full-service capability without placing your study at a distance. We work alongside your team, adapt as evidence develops and keep accountability clear.
Case study: accelerating recruitment for a Phase I oncology study
Clarenta supported a Phase I clinical pharmacology study requiring accelerated recruitment, intensive PK sampling and precise coordination with patients’ chemotherapy schedules. Through an integrated recruitment and site-support model, including experienced research nurses, dedicated site management and study coordination, the centre managed the demanding procedures and enrolled 36 patients in approximately two months.
Early phase oncology trials FAQs
An early phase oncology trial is a clinical study that evaluates a new cancer therapy in patients while establishing safety, tolerability, dose and early evidence of biological or clinical activity. It may include first-in-human, Phase I, Phase Ib or early Phase II development, with dose escalation, optimisation or expansion cohorts informed by emerging safety, PK/PD, biomarker and response data.
An oncology CRO is a clinical research organisation with the scientific and operational capability to plan and deliver cancer trials. For early phase studies, this should include oncology study design, dose and cohort strategy, regulatory support, specialist site selection, patient recruitment planning, medical monitoring, pharmacovigilance, data review, biostatistics and clinical operations that can adapt as evidence emerges.
A Phase I oncology trial evaluates safety and tolerability, characterises PK/PD and supports selection of a dose or dose range for further development. Depending on the asset and design, it may also assess biomarkers, exposure-response, patient experience and preliminary antitumour activity. The objective is to support a clear development decision, not simply to identify the highest tolerated dose.
Design begins with the therapy, mechanism, non-clinical evidence, expected toxicity, patient population and development question. The protocol then defines the starting dose, escalation method, cohort rules, safety review, PK/PD and biomarker assessments, stopping criteria and any backfill, optimisation or expansion cohorts. Rule-based, model-assisted and model-based approaches may be considered; the right choice depends on the asset and context.
Recruitment starts with realistic feasibility at indication and molecular-subtype level. The strategy should assess standards of care, competing trials, referral pathways, diagnostic and biomarker testing, prior-treatment requirements, screen-failure risks and site capacity. Specialist centres are selected for both access to potentially eligible patients and the ability to perform the protocol’s procedures safely and reliably.
There is no single standard duration. Timelines depend on the indication, eligible population, number and size of cohorts, dose-review cadence, site and country mix, start-up requirements, protocol amendments and recruitment performance. A useful plan models these drivers and defines decision points rather than relying on one fixed enrolment assumption.
Key cost drivers include the number of countries, sites and cohorts; recruitment duration; visit and safety-monitoring intensity; imaging, biomarker and laboratory requirements; investigational product and supply needs; external vendors; data-review cadence; and amendment scenarios. Early design and feasibility work can expose the choices that most affect cost before the protocol becomes difficult to change.
Look for relevant oncology and early phase experience, a credible dose and cohort strategy, evidence of patient and site access, regulatory knowledge in the intended countries, strong medical and safety oversight, decision-ready data processes and clear governance. Ask who will lead the study, how senior specialists remain involved and how the CRO has handled recruitment, cohort changes and amendments in comparable programmes.
An integrated model reduces handoffs between strategy, regulatory, operations, medical, safety, data and statistics. This matters when new evidence changes a cohort, amendment or site instruction. With shared governance and clear ownership, the teams supporting the decision can assess its scientific and operational effects together and act with less delay.